Net product revenue of $42.1M in 4Q and $50.7M for the year
• New England Journal of Medicine publication of the use of B-VEC eyedrop formulation
• Reached alignment with FDA to enable approval of B-VEC eyedrop formulation for the treatment of lesions in the eye of DEB patients
• First patient dosed in Phase 1 KB408 trial for the treatment of AATD; five active clinical trials in 2024
• Strong balance sheet, closing the year with $594.1M in cash and investments
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.